MBX Biosciences, Inc. (NASDAQ:MBX) Receives $50.20 Average Price Target from Brokerages

MBX Biosciences, Inc. (NASDAQ:MBX) has been given a consensus recommendation of “Moderate Buy” by the thirteen analysts that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation and eleven have issued a buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $50.20.

A number of research analysts recently weighed in on MBX shares. Barclays began coverage on shares of MBX Biosciences in a research report on Tuesday, January 27th. They set an “overweight” rating and a $66.00 price objective on the stock. Truist Financial began coverage on MBX Biosciences in a report on Wednesday, October 15th. They set a “buy” rating and a $50.00 price target on the stock. UBS Group assumed coverage on MBX Biosciences in a research note on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price target on the stock. Stifel Nicolaus upped their price objective on MBX Biosciences from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of MBX Biosciences in a report on Thursday, January 22nd.

MBX Biosciences Price Performance

MBX Biosciences stock opened at $37.67 on Wednesday. MBX Biosciences has a one year low of $4.81 and a one year high of $44.89. The firm’s fifty day simple moving average is $33.97. The stock has a market capitalization of $1.69 billion, a PE ratio of -15.76 and a beta of 0.87.

MBX Biosciences (NASDAQ:MBX) last posted its earnings results on Thursday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.10.

Institutional Trading of MBX Biosciences

Several large investors have recently added to or reduced their stakes in MBX. ProShare Advisors LLC purchased a new stake in MBX Biosciences during the fourth quarter valued at approximately $227,000. UBS Group AG grew its position in shares of MBX Biosciences by 363.1% during the 4th quarter. UBS Group AG now owns 281,212 shares of the company’s stock valued at $8,869,000 after acquiring an additional 220,487 shares during the period. Vanguard Group Inc. raised its holdings in MBX Biosciences by 8.4% in the 4th quarter. Vanguard Group Inc. now owns 1,817,811 shares of the company’s stock worth $57,334,000 after purchasing an additional 140,449 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in MBX Biosciences by 206.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 15,317 shares of the company’s stock worth $483,000 after purchasing an additional 10,317 shares during the period. Finally, GF Fund Management CO. LTD. purchased a new position in MBX Biosciences during the fourth quarter valued at $28,000.

About MBX Biosciences

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.